Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

University of Maryland, Baltimore · 2021
ClinicalTrials.gov · Datasets · License: Public Domain · 2021
Open Source ↗
overall-survival
relapsed/refractory multiple myeloma, belantamab mafodotin, maximum tolerated doses, overall response rate, overall survival, dose limiting toxicities, interventional, phase1, phase2
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 856337
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.